Our Team

Olivier Laczka

Chief Scientific Officer

BSc, MSc, PhD

Dr Laczka obtained a PhD in Biotechnology from the Autonomous University of Barcelona, Spain, in 2009, after completing a master’s degree in applied biotechnology and microbiology and a bachelor’s degree in biological sciences in France. For the first part of his career, Olivier conducted research as an academic, in Spain and Australia, where he was able to successfully develop diagnostic tools toward a wide range of applications, going from medical and food diagnostics to both terrestrial and marine monitoring devices, generating over 25 peer-reviewed research articles and a patent. In 2012, he was awarded the prestigious University of Technology Sydney (UTS) Vice Chancellor’s Postdoctoral Research Fellowship, which enabled him to carry out extensive independent research on the development of novel methods toward the detection of human pathogens.

Dr Laczka’s expertise covers an extensive range of technical skills in microscopy, chemical, electrochemical and optical methods, microbiology, biochemistry, immunology, and molecular biology. In 2015, he joined the Biopharmaceutical industry as a senior research scientist, where he successfully managed and completed therapeutic drug development projects within GLP and cGMP environments, following the current regulatory requirements for early stages of drug development. Dr Laczka’s multidisciplinary background allows him to drive projects covering a wide range of technologies and indications. Throughout his career, Olivier has developed an extensive experience in people and project management, as well as interacting with academic, government, and private entities or individuals, at the international level. His scientific writing experience has also allowed him to attract significant amounts of research funding over the years, through collaborations and partnerships with private entities and government organizations.

Assoc. Prof. Michael P. Gantier

Scientific Advisor

MEng (Biol), PhD.

Associate Professor Michael Gantier leads the Nucleic Acids and Innate Immunity laboratory in the Centre for Innate Immunity and Infectious Disease at the Hudson Institute of Medical Research. The central theme of his research is to define how nucleic acids (RNA and DNA) modulate immune responses. He was trained as a biological engineer in Compiegne, France, prior to undertaking his PhD in Medicine and Therapeutics in University College Dublin with Prof. Seamas Donnelly, working on the then emerging RNA interference technology. 

Following on his PhD studies he joined the laboratory of Prof Bryan Williams in 2006, to define the interaction of RNAs with the innate immune system. This led to the discoveries of structural determinants of RNAs which underlie their capacity to activate or inhibit immune responses by Toll Like Receptors, a theme he has developed further in his independent laboratory since 2015. 

More recently, his laboratory discovered how immune responses could be engaged in damaged cells, with implications in infection, immunity, and cancer - through the engagement of the cGAS-STING pathway.

In 2015, following the award of an ARC Future Fellowship and several NHMRC project grants, he was promoted to lead his own research group in the Hudson Institute of Medical Research and in 2020 was promoted to Associate Professor.

He received the prestigious Milstein Young Investigator award from the International Cytokine and Interferon Society (2010), and Oligonucleotide Therapeutics Society Young Investigator award (2014) among several other international and national awards. He has published over 70 peer-reviewed publications, and is an inventor on 5 PCT patents. He currently serves as Associate Editor for the prestigious Molecular Therapy-Nucleic Acids journal and Journal of Interferon and Cytokine Research. 

Associate Professor Gantier’s team made the ground-breaking discovery that idronoxil was a potent inhibitor of TBK1, effectively blocking STING and MAVS signalling, at the root of the NOXCOVID trial.

Daniel Wenholz

Pharmaceutical Chemist

BSc Hons; PhD.

After finishing a Bachelor of Science at UTS, Daniel worked for 2 years in an Environmental Chemistry role in Canberra. He returned to Sydney in 2016 to obtain a PhD degree in Medicinal Chemistry funded by a UNSW Research Excellence Award.

After the completion of his PhD, Daniel entered an academic position at UNSW funded by Noxopharm where he helped guide the chemistry direction and strategies of the drug discovery program. Daniel was then able to officially join Noxopharm as Pharmaceutical Chemist in 2020 before more recently taking on the role of Director of Pharmaceutical Chemistry. In this position he has driven the pharmaceutical chemistry efforts on multiple projects and oversees every aspect of the drug discovery alongside the biology-focused Noxopharm team members.

Daniel maintains close links with UNSW Sydney with a recently appointed Visiting Fellow position that allows for further collaboration between Noxopharm and the University.

Graham Kelly

Director

BSc (Vet) (Hons, BVSc (Hons), PhD

Graham graduated with degrees in Science (1968) and Veterinary Science (1969) from The University of Sydney. After graduation he joined the newly-formed Department of Transplant Surgery in the Faculty of Medicine at The University of Sydney, gaining a Doctor of Philosophy in 1972. The subject of his PhD thesis was the manufacture and use of a novel drug for the treatment of tissue rejection in kidney transplant recipients, with that drug subsequently being commercialised and used globally in kidney transplantation. Graham was appointed Senior Research Fellow in Experimental Surgery at The University of Sydney, contributing through research in the areas of organ recovery for transplantation and liver transplant surgery. The increased susceptibility of organ transplant recipients to malignant cancer eventually led Graham to focus on the causes of that phenomenon, and in turn, to the broader issue of the link between diet and the incidences of certain cancers. The latter area of research led to a research interest in dietary isoflavones and their role in human health.

Graham developed a theory that dietary isoflavones were metabolised within the body into novel chemicals that possessed important hormone-like functions, and as such made important contributions to human health. That theory provided the basis for Graham leaving academia and founding the company, Norvet Ltd, which listed on the ASX in 1994. That company subsequently changed its name to Novogen Ltd and listed in the US on NASDAQ (1998). Graham was variously CEO, Executive Chairman and an Executive Director of Novogen, 1994-2006. He also was Executive Chairman of Marshall Edwards Inc (MEI) which listed on London’s AIM exchange (2001) and NASDAQ (2003). MEI subsequently became MEI Pharma Inc. Graham resigned from his executive and Board positions at Novogen and MEI in 2006.

In early-2012, Graham addressed the matter of the transport of isoflavones in the blood of humans, conducting formulation studies in a private capacity that led shortly thereafter to the concept behind NOX66. After leaving Novogen in 2015, Graham established private biotechnology company Noxopharm Pty Ltd in order to commercialise NOX66 (Veyonda®).

Noxopharm Limited listed on the Australian Securities Exchange (ASX) in August 2016.
Graham was also the founder of a fourth biotechnology company, Nyrada Inc. in September 2017. Nyrada (ASX:NYR) became a public company in January 2020. Nyrada is a drug development company with a focus on cardiovascular and traumatic brain injury treatments. Noxopharm is currently the major shareholder.

Cameron Jones

Chief Financial Officer & Company Secretary

CA, BBus, GIA(Cert)

Cameron is the Managing Director of Bio101, a financial services firm providing accounting, tax and company secretarial services specialising in the healthcare and life science sectors. A qualified Chartered Accountant and registered tax agent, Cameron acts as CFO and Company Secretary for a number of ASX listed life science companies and Venture Capital investee companies. In his role at Bio101 Cameron has assisted a number of clients in the IPO process and fills the role and acts as Australian Resident Director.

Cameron is a Director and Treasurer of registered charities Cystic Fibrosis Community Care Ltd (CFCC) and BioAutism Ltd and Chair of the Investment Committee for CFCC.